Literature DB >> 9826651

In vitro selection of RNA molecules that displace cocaine from the membrane-bound nicotinic acetylcholine receptor.

H Ulrich1, J E Ippolito, O R Pagán, V A Eterović, R M Hann, H Shi, J T Lis, M E Eldefrawi, G P Hess.   

Abstract

The nicotinic acetylcholine receptor (AChR) controls signal transmission between cells in the nervous system. Abused drugs such as cocaine inhibit this receptor. Transient kinetic investigations indicate that inhibitors decrease the channel-opening equilibrium constant [Hess, G. P. & Grewer, C. (1998) Methods Enzymol. 291, 443-473]. Can compounds be found that compete with inhibitors for their binding site but do not change the channel-opening equilibrium? The systematic evolution of RNA ligands by exponential enrichment methodology and the AChR in Torpedo californica electroplax membranes were used to find RNAs that can displace inhibitors from the receptor. The selection of RNA ligands was carried out in two consecutive steps: (i) a gel-shift selection of high-affinity ligands bound to the AChR in the electroplax membrane, and (ii) subsequent use of nitrocellulose filters to which both the membrane-bound receptor and RNAs bind strongly, but from which the desired RNA can be displaced from the receptor by a high-affinity AChR inhibitor, phencyclidine. After nine selection rounds, two classes of RNA molecules that bind to the AChR with nanomolar affinities were isolated and sequenced. Both classes of RNA molecules are displaced by phencyclidine and cocaine from their binding site on the AChR. Class I molecules are potent inhibitors of AChR activity in BC3H1 muscle cells, as determined by using the whole-cell current-recording technique. Class II molecules, although competing with AChR inhibitors, do not affect receptor activity in this assay; such compounds or derivatives may be useful for alleviating the toxicity experienced by millions of addicts.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9826651      PMCID: PMC24324          DOI: 10.1073/pnas.95.24.14051

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  62 in total

1.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase.

Authors:  C Tuerk; L Gold
Journal:  Science       Date:  1990-08-03       Impact factor: 47.728

Review 2.  Functional architecture of the nicotinic acetylcholine receptor: from electric organ to brain.

Authors:  J L Galzi; F Revah; A Bessis; J P Changeux
Journal:  Annu Rev Pharmacol Toxicol       Date:  1991       Impact factor: 13.820

3.  In vitro selection of RNA molecules that bind specific ligands.

Authors:  A D Ellington; J W Szostak
Journal:  Nature       Date:  1990-08-30       Impact factor: 49.962

4.  MK-801 inhibition of nicotinic acetylcholine receptor channels.

Authors:  M Amador; J A Dani
Journal:  Synapse       Date:  1991-03       Impact factor: 2.562

Review 5.  The dopamine hypothesis of the reinforcing properties of cocaine.

Authors:  M J Kuhar; M C Ritz; J W Boja
Journal:  Trends Neurosci       Date:  1991-07       Impact factor: 13.837

6.  Autoradiography using storage phosphor technology.

Authors:  R F Johnston; S C Pickett; D L Barker
Journal:  Electrophoresis       Date:  1990-05       Impact factor: 3.535

7.  Properties, in theory and practice, of novel gel filtration media for standard liquid chromatography.

Authors:  L Hagel; H Lundström; T Andersson; H Lindblom
Journal:  J Chromatogr       Date:  1989-08-04

8.  Voltage jump analysis of procaine action at frog end-plate.

Authors:  P R Adams
Journal:  J Physiol       Date:  1977-06       Impact factor: 5.182

9.  The anticonvulsant MK-801 interacts with peripheral and central nicotinic acetylcholine receptor ion channels.

Authors:  A S Ramoa; M Alkondon; Y Aracava; J Irons; G G Lunt; S S Deshpande; S Wonnacott; R S Aronstam; E X Albuquerque
Journal:  J Pharmacol Exp Ther       Date:  1990-07       Impact factor: 4.030

View more
  24 in total

1.  Mechanism-based discovery of ligands that counteract inhibition of the nicotinic acetylcholine receptor by cocaine and MK-801.

Authors:  G P Hess; H Ulrich; H G Breitinger; L Niu; A M Gameiro; C Grewer; S Srivastava; J E Ippolito; S M Lee; V Jayaraman; S E Coombs
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

Review 2.  Recent advances in understanding oligonucleotide aptamers and their applications as therapeutic agents.

Authors:  Khaled S Allemailem; Ahmad Almatroudi; Mohammed A Alsahli; Ghaiyda Talal Basfar; Faris Alrumaihi; Arshad Husain Rahmani; Amjad Ali Khan
Journal:  3 Biotech       Date:  2020-11-24       Impact factor: 2.406

3.  Strategies for the discovery of therapeutic aptamers.

Authors:  Xianbin Yang; Na Li; David G Gorenstein
Journal:  Expert Opin Drug Discov       Date:  2011-01       Impact factor: 6.098

4.  RNA aptamers and their therapeutic and diagnostic applications.

Authors:  Katherine Germer; Marissa Leonard; Xiaoting Zhang
Journal:  Int J Biochem Mol Biol       Date:  2013-03-31

5.  Aptamers that preferentially bind type IVB pili and inhibit human monocytic-cell invasion by Salmonella enterica serovar typhi.

Authors:  Qin Pan; Xiao-Lian Zhang; Hong-Yan Wu; Pan-Wen He; Fubin Wang; Ming-Sheng Zhang; Jian-Ming Hu; Bing Xia; Jianguo Wu
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

6.  Selection of 2'-fluoro-modified RNA aptamers for alleviation of cocaine and MK-801 inhibition of the nicotinic acetylcholine receptor.

Authors:  Y Cui; H Ulrich; G P Hess
Journal:  J Membr Biol       Date:  2004-12       Impact factor: 1.843

Review 7.  Intracellular delivery of RNA-based therapeutics using aptamers.

Authors:  Kristina W Thiel; Paloma H Giangrande
Journal:  Ther Deliv       Date:  2010-12

Review 8.  Searching for interesting channels: pairing selection and molecular evolution methods to study ion channel structure and function.

Authors:  Daniel L Minor
Journal:  Mol Biosyst       Date:  2009-06-19

9.  Development of the anti-VEGF aptamer to a therapeutic agent for clinical ophthalmology.

Authors:  Cleber A Trujillo; Arthur A Nery; Janaína M Alves; Antonio H Martins; Henning Ulrich
Journal:  Clin Ophthalmol       Date:  2007-12

10.  Water soluble RNA based antagonist of AMPA receptors.

Authors:  Mei Du; Henning Ulrich; Xiurong Zhao; Jaroslaw Aronowski; Vasanthi Jayaraman
Journal:  Neuropharmacology       Date:  2007-05-21       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.